Tevogen Demonstrates Platform Scalability and Multi-Indication T Cell Pipeline Expansion in 2025

Rhea-AI Summary

Tevogen (Nasdaq: TVGN) reported 2025 scientific and operational milestones focused on scaling its ExacTcell™ T cell platform, expanding cytotoxic T lymphocyte (CTL) programs across viral and oncology indications, and advancing in-house GMP cell therapy manufacturing readiness. 2025 achievements include improved lab yields per product, T cell target identification for five additional HLA restrictions for SARS-CoV-2 CTLs, and target discovery work for EBV, chronic hepatitis B, and HPV-related cancers supported by Tevogen.AI.

Management highlighted platform scalability, pipeline breadth, manufacturing foundation, and plans to discuss AI, financial strategy, and commercialization at J.P. Morgan.

News Market Reaction

-16.45% 2.6x vol

27 alerts

-16.45% News Effect

-15.6% Trough in 5 hr 16 min

-$14M Valuation Impact

$73M Market Cap

2.6x Rel. Volume

On the day this news was published, TVGN declined 16.45%, reflecting a significant negative market reaction. Argus tracked a trough of -15.6% from its starting point during tracking. Our momentum scanner triggered 27 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $14M from the company's valuation, bringing the market cap to $73M at that time. Trading volume was elevated at 2.6x the daily average, suggesting increased selling activity.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

New HLA restrictions: 5 additional HLA restrictions Q3 2025 net loss: $5,726,812 Nine‑month 2025 net loss: $21,597,852 +5 more

8 metrics

New HLA restrictions 5 additional HLA restrictions Expanded target coverage for SARS-CoV-2-specific CTL product in 2025

Q3 2025 net loss $5,726,812 Net loss for quarter ended September 30, 2025 (424B3/10-Q)

Nine‑month 2025 net loss $21,597,852 Net loss for nine months ended September 30, 2025 (424B3)

Cash balance $1,037,094 Cash as of September 30, 2025 (424B3)

ATM program size $50,000,000 At-the-market Sales Agreement entered July 3, 2025

ATM net proceeds $3.9 million Net proceeds through November 12, 2025

Related‑party loan outstanding $4,400,000 Outstanding on related‑party loan agreement (Q3 2025)

Grant commitment remaining $7.0 million KRHP grant commitment expected to support at least 12 months of operations

Market Reality Check

Price: $0.3138 Vol: Volume 2,094,114 is 3.23x...

high vol

$0.3138 Last Close

Volume Volume 2,094,114 is 3.23x the 20-day average of 649,337, indicating elevated trading interest ahead of this update. high

Technical Shares at 0.389 trade below the 200-day MA of 0.87 and remain close to the 0.299 52-week low, far from the 1.92 52-week high.

Peers on Argus

TVGN was modestly lower (-0.26%) while key biotech peers like KYTX (-3.26%), CRB...

TVGN was modestly lower (-0.26%) while key biotech peers like KYTX (-3.26%), CRBU (-3.49%), and IPHA (-4.86%) also declined, but there was no confirmed sector-wide momentum signal.

Common Catalyst Some peers, such as KYTX, also issued J.P. Morgan Healthcare Conference corporate updates, but these appear company-specific rather than a unified sector catalyst.

Historical Context

5 past events · Latest: Dec 22 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 22	Charitable share donation	Positive	+1.4%	CEO donated 230,000 shares to nonprofit supporting underprivileged children.
Dec 19	Charitable share donation	Positive	-0.3%	CEO donated 50,000 personal shares to support local fire department.
Dec 11	Charitable share donation	Positive	-1.8%	CEO gifted 230,000 personal shares to local law enforcement charity.
Dec 11	Board recognition	Positive	+3.5%	Yale honored board member; company reiterated ExacTcell™ and >$1B revenue outlook.
Dec 08	Corporate recognition	Positive	+8.8%	NJBIZ Power List recognition with multi‑billion‑dollar revenue forecasts and expansion.

Pattern Detected

Recent news has been largely promotional or philanthropic, with mixed short-term price reactions—some positive alignment on recognition/growth stories and divergences around insider share donations.

Recent Company History

Over the last months of 2025, Tevogen highlighted recognition on the 2025 New Jersey Power List with multi‑billion‑dollar revenue forecasts, honored a board member tied to advances in the ExacTcell™ platform, and disclosed several large charitable share donations by leadership. Regulatory filings showed continued net losses and tight liquidity. Today’s update on ExacTcell™ scalability, CTL pipeline expansion, and manufacturing readiness continues this narrative of platform building and long‑term growth positioning.

Market Pulse Summary

The stock dropped -16.4% in the session following this news. A negative reaction despite operational...

Analysis

The stock dropped -16.4% in the session following this news. A negative reaction despite operational progress would fit a pattern where upbeat narratives sometimes met with weakness, as seen after prior charitable share donations with -0.26% and -1.78% moves. The update emphasizes ExacTcell™ scalability and broader CTL targets, but filings show a Q3 net loss of $5.73 million and limited cash of about $1.04 million, so balance sheet constraints could dominate sentiment over long-term platform potential.

Key Terms

cytotoxic t lymphocyte, sars-cov-2, hla restrictions, epstein-barr virus, +3 more

7 terms

cytotoxic t lymphocyte medical

"expanded its cytotoxic T lymphocyte (CTL) pipeline across multiple viral and oncology indications"

A cytotoxic T lymphocyte is a type of white blood cell that seeks out and kills cells infected by viruses or cells that have become abnormal, like cancer cells. Think of them as targeted security guards that recognize and destroy threats without harming the whole building. For investors, their role matters because therapies that boost or harness these cells are central to many drug candidates, affect clinical trial outcomes, safety profiles, and can drive regulatory approvals and company value.

sars-cov-2 medical

"Building on its SARS-CoV-2 proof-of-concept clinical experience, Tevogen completed T cell target identification"

SARS-CoV-2 is the virus that causes the illness known as COVID-19; think of it as a biological engine that can start chains of sickness in people. It matters to investors because its spread and the measures taken to control it—such as changes to workforce availability, consumer demand, supply chains, travel, and healthcare spending—can quickly alter company revenues, costs and regulatory priorities, much like a sudden storm that affects many parts of an economy at once.

hla restrictions medical

"completed T cell target identification for five additional HLA restrictions, significantly expanding potential patient coverage"

HLA restrictions describe when a therapy, vaccine, or immune-based test works only in people who carry particular human leukocyte antigen (HLA) types, because those immune-signature proteins determine whether the treatment’s mechanism can be recognized or activated. For investors this matters because it narrows the pool of eligible patients, affects clinical trial recruitment and approval strategy, and constrains potential sales — like a key that opens only certain locks rather than every door.

epstein-barr virus medical

"CTL therapies addressing: Epstein-Barr virus (EBV) associated lymphomas"

A common human virus that often causes infectious mononucleosis and can remain dormant in the body; think of it like a household pest that usually causes minor trouble but can flare up or lead to complications for some people. Investors watch it because outbreaks, new tests, treatments, or vaccine progress can affect demand for medical services, drug and diagnostic company revenues, clinical trial results, and regulatory decisions that influence healthcare and biotech stock values.

chronic hepatitis b medical

"Chronic hepatitis B, including programs focused on prevention of virus-associated hepatic diseases and cancer"

Chronic hepatitis B is a long-term viral infection of the liver where the hepatitis B virus persists and causes ongoing liver inflammation and damage, like a smoldering fire that can slowly weaken the organ over years. It matters to investors because it defines a steady, large market for treatments and diagnostics, shapes regulatory and clinical trial risks, and influences healthcare costs and the potential value of companies developing new therapies.

human papilloma virus medical

"Human Papilloma Virus (HPV) related cancers Target discovery efforts were supported by Tevogen.AI"

A group of related viruses that commonly infect the skin and lining of the body; some types cause harmless warts while certain strains can lead to cancers such as cervical and throat cancer. Investors watch HPV because vaccines, screening tests and treatments can prevent disease and create steady markets, and changes in public health guidance or regulatory approvals can quickly affect demand and company revenues—think of it like different models in a car line where some are low-risk and others need safety recalls or upgrades.

gmp regulatory

"advanced its strategy to establish in-house GMP cell therapy manufacturing capabilities"

Good Manufacturing Practice (GMP) is a set of regulatory standards and procedures that ensure products—especially medicines, medical devices, and related goods—are consistently made to meet safety, quality, and purity requirements. For investors, GMP compliance is like a factory’s hygiene and checklist system: it reduces the risk of product recalls, regulatory fines, and production stoppages, supports market access, and signals more reliable, lower-risk operations that can protect revenue and reputation.

AI-generated analysis. Not financial advice.

Jan. 12, 2026, San Francisco. Issued from the J.P. Morgan Healthcare Conference

WARREN, N.J., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today reported significant scientific and operational milestones achieved in 2025 within its biotechnology operations, reflecting Tevogen’s continued execution toward a scalable, established, multi-program cell therapy development organization.

In 2025, Tevogen advanced its proprietary ExacTcell™ platform, expanded its cytotoxic T lymphocyte (CTL) pipeline across multiple viral and oncology indications, and advanced its strategy to establish in-house GMP cell therapy manufacturing capabilities.

Platform Scalability and Manufacturing Readiness:

Tevogen reported enhancements to ExacTcell™ that increased laboratory yields of target-specific CTLs per product, supporting improved consistency and throughput. These improvements are intended to enable efficient clinical supply and support future clinical and commercial manufacturing across multiple programs using shared infrastructure.

Pipeline Expansion Across Multiple Indications:

Building on its SARS-CoV-2 proof-of-concept clinical experience, Tevogen completed T cell target identification for five additional HLA restrictions, significantly expanding potential patient coverage for its SARS-CoV-2-specific CTL product.

Tevogen also advanced target discovery and preclinical activities supporting CTL therapies addressing:

• Epstein-Barr virus (EBV) associated lymphomas
• Chronic hepatitis B, including programs focused on prevention of virus-associated hepatic diseases and cancer
• Human Papilloma Virus (HPV) related cancers
  
  

Target discovery efforts were supported by Tevogen.AI, the Company’s advanced analytics division, which, among its broader analytical capabilities, supports peptide target identification, refinement, and prioritization across CTL programs.

Positioned for Value Creation:

“2025 was a defining execution year for Tevogen,” said Ryan Saadi, Founder and CEO of Tevogen. “We have built a scalable CTL platform, expanded into multiple high-value indications, and laid the manufacturing foundation required to translate our science into clinical and commercial outcomes. Tevogen is different by design, and during the J.P. Morgan Healthcare Conference we look forward to sharing additional updates on our AI capabilities, financial strategy, commercialization outlook, and future expansion plans.”

Tevogen’s management believes these milestones reflect measurable progress across, platform scalability, pipeline breadth, manufacturing readiness, and long-term value drivers.

About Tevogen

Tevogen is a next-generation, socially integrated healthcare enterprise built on the principles of affordability, efficiency, and scientific rigor. The company leverages industry-leading artificial intelligence and precision T cell therapy platforms, a patient-first and cost-disciplined operating model, and strategic engagements with global technology leaders to support the development of advanced, life-saving therapies across multiple therapeutic areas and scalable solutions for the broader healthcare system.

Tevogen Bio, the company’s lead initiative, has completed a proof-of-concept clinical trial demonstrating the potential of its single-HLA-restricted, genetically unmodified allogeneic T cells. The Tevogen Bio pipeline spans virology, oncology, and neurology, with programs built on the company’s proprietary ExacTcell™ platform.

Tevogen.AI is designed to transform drug development by accelerating target detection, helping reduce failure rates, and supporting optimized clinical trial design through proprietary predictive technologies. The platform utilizes cloud and data services from leading technology providers, including Microsoft and Databricks, to advance its long-term ambition to predict the proteome for any given protein–HLA combination, enabling rapid and cost-efficient therapeutic discovery.

Tevogen is exploring future strategic initiatives that may include domestic generics, biosimilars, medical devices, and innovative insurance solutions for healthcare providers. Together, these programs reflect Tevogen’s mission to advance sustainable innovation and broaden patient access through a faster, more efficient, and more equitable healthcare model.

Forward Looking Statements

This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen’s plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.

Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; that Tevogen will need to raise additional capital to fully realize its business plans; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K and subsequent filings with the SEC.

You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.

Contacts

Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com

FAQ

What platform improvements did Tevogen announce for ExacTcell in 2025 (TVGN)?

Tevogen said ExacTcell enhancements increased laboratory yields of target-specific CTLs per product, improving consistency and throughput.

How did Tevogen expand SARS-CoV-2 CTL coverage in 2025 for TVGN?

Tevogen completed T cell target identification for five additional HLA restrictions to expand potential patient coverage for its SARS-CoV-2-specific CTL product.

Which new indications did Tevogen advance in 2025 under TVGN?

Tevogen advanced target discovery and preclinical activities for EBV-associated lymphomas, chronic hepatitis B (including virus-associated hepatic disease and cancer), and HPV-related cancers.

What role does Tevogen.AI play in Tevogen's 2025 CTL programs (TVGN)?

Tevogen.AI supported peptide target identification, refinement, and prioritization across CTL programs as part of target discovery efforts.

What manufacturing progress did Tevogen report in 2025 for TVGN?

Tevogen advanced its strategy to establish in-house GMP cell therapy manufacturing capabilities to support clinical supply and potential future commercial production.